You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb. Follow her on Twitter at @Julia_Karow.
Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
Several labs and at least one company have been working on assays that add samples directly to the PCR reaction and don't require RNA extraction, a time-consuming step.
The firm plans to submit an EUA application for its quantitative Sanger sequencing COVID-19 test, which could run on hundreds of available CE instruments.
The test, developed by the firms in six weeks, is part of a viral respiratory panel and runs on Bosch's point-of-care Vivalytic system.
The company is "highly confident" that the deal, which is expected to close in the first half of 2021, will be approved by regulatory authorities.
The technology uses single-cell droplet digital PCR to analyze maternal blood cell populations that have been enriched for fetal cells by MACS.